The purpose of this research study is to study if the investigational drug, MK-6194, is safe and effective to treat adults with non-segmental vitiligo. In this study, MK-6194 or placebo administration will occur every two weeks or every four weeks to evaluate how well MK-6194 may treat non-segmental vitiligo. This study can last up to 60 weeks, including up to 4 weeks for screening, up to 52 weeks for treatment, and 14 days for safety follow-up. Eligible participants will be randomized 1:1:1 to receive MK-6194 every two weeks, every four weeks, or receive placebo.

The purpose of this study is to evaluate the efficacy of eltrekibart compared to placebo in adults with moderate to severe HS. The study duration will be up to 67 weeks. This study includes a screening period, a 16-week double-blind, placebo-controlled treatment period, a 36-week double-blind maintenance treatment period, and a 10-week follow-up period.

This study is designed to evaluate the safety and effectiveness of using a combination of two different medications (extended release naltrexone and bupropion) compared to matching placebo (an inactive substance) in the treatment of methamphetamine use disorder. Participants will undergo screening, and if eligible, will receive study medications along with brief medication management for twelve weeks, with follow up visits at weeks 14 and 16. The total study duration is around 19 weeks.

This study is enrolling subjects with non-obstructive hypertrophic cardiomyopathy (nHCM). nHCM is typically a genetic condition in which the main pumping chamber of the heart (called the left ventricle) becomes abnormally thickened and stiff, which makes it harder for the ventricle to fill and pump out enough blood. This study involves the investigational medication Aficamten, which means it is not approved for commercial use by the Food and Drug Administration. (FDA) Aficamten is designed to reduced excessive heart pumping function. This is a randomized study which means all subjects are assigned to receive either Aficamten or placebo. Subjects have a 50:50 chance of being assigned to either group, but will not know which group they are assigned. Placebo looks like the medication but does not have any active ingredients in it. Study procedures include exercise testing, echocardiograms (ultrasound test of the heart), blood work, questionnaires and genetic testing. Study risks include risks associated with the study medication including decreased heart pumping, nausea, headache and dizziness. There are also study procedure related risks, and the risk of loss of confidentiality. There may be no benefit but the information learned may benefit others in the future. Study participation will last between 10.5 and 19 months and include up to 13 visits to the study site. Visits will generally last 2-3 hours.

The study seeks to evaluate the effectiveness of ARINA-1, an investigational inhaled medication, in reducing cough and mucus production in patients who are diagnosed with chronic bronchitis. If enrolled in this study, there will be four clinic visits, one telehealth visit, and one phone call. As part of the study assessments, a cough monitor will be worn on the wrist, as well as repeat spirometry, questionnaires, and bloodwork will be completed. The ARINA-1 will administered with a nebulizer provided to participants and is taken twice daily for 28 days. The total duration of this study is up to 12 weeks for each enrolled participant.

Compensation will be provided for your time for each visit that is completed.

This study involves research. You are being asked to participate in this research study to have your temperature taken. The purpose of the study is to collect data to test a temperature measurement module that is part of medical study device that measure's human body temperature.

The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with investigational urine testing. Specifically, we are examining whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.

This Phase 3 study, comprising a double-blind, placebo-controlled treatment period of up to 48 weeks, will assess the efficacy and safety of seralutinib versus placebo when added to background PAH disease-specific medication in adult PAH subjects who are WHO FC II or III. The primary objective of the study is to assess the efficacy of seralutinib relative to placebo with a primary endpoint of change from baseline to Week 24 in 6MWD.

This trial is for people with melanoma. This trial is testing the V940 (mRNA-4157) vaccine given in combination with pembrolizumab in people who have surgery to remove their melanoma. The vaccine has multiple patient-specific neoantigens that could improve the recurrence-free survival after the surgery. Each participant will participate in the study for approximately 7 years from the time the participant provides full documented informed consent through the final contact. There is a screening window of up tp 56 days where the participants receives tumor scan, brain scan, pathology report, hematology, coagulation tests, hormones, enzymes, and blood for genetic sequencing and vaccine generation. After a screening period of up to 56 days, each participant will be receiving assigned intervention for a maximum of approximately 56 weeks. The participants will be assigned to the two arms in the study randomly after the genetic testing confirms eligibility based on disease risk and age. Arm A will receive and a V940 injection in the muscle every 3 weeks for a total of 9 doses and pembrolizumab ever 6 weeks for a total of 9 cycles. Arm B will receive Placebo every 3 weeks for 9 dose and pembrolizumab every 6 weeks for 9 cycles. After the end of treatment each participant will be followed for approximately 6 years. V940 monotherapy has been well tolerated, but injection site observations included edema and pain/tenderness, and systemic inflammatory observations, including flu like symptoms, fever, fatigue, and myalgias/arthralgias, all of which have typically resolved 1 to 2 days after dosing). The clinical safety profile of V940 does not significantly overlap with pembrolizumab. Pembrolizumab has a positive benefit-risk profile and is well tolerated. Some possible risks associated with pembrolizumab are fatigue, pruritus , rash , diarrhea, nausea, hypothyroidism, pneumonitis, colitis, pyrexia and autoimmune hepatitis, pneumonia, adrenal insufficiency and hyponatremia.

This study is for patients that have been diagnosed with early-stage (Stage I or II) Hodgkin lymphoma (HL)(cHL). The main purpose of this study is to compare the effects, good and/or bad, of brentuximab vedotin and nivolumab (Bv-NIVO) against standard therapy for people with HL to find out which is better. Participants can expect to be in the study for up to 54 months.